次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

変形性関節症治療薬の世界市場:部位別、薬剤タイプ別2024年予測

Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2019年10月
定価 Single User License(1名様ライセンス)US$4,950(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文148ページになります。
商品コード:MAM1722

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
変形性関節症治療薬の世界市場規模は2019年の推計68億ドルから、今後2024年には101億ドルにまで増加すると予測されます。当レポートでは、2024年に至る変形性関節症治療薬の世界市場予測(市場規模US$)、部位別市場(変形性膝関節症、変形性股関節症、変形性手関節症、変形性小関節症)、薬剤タイプ別市場(関節内補充薬、非ステロイド性抗炎症薬各種、鎮痛薬各種、コルチコステロイド)、投薬経路別市場(経口、非経口、局所)、流通経路別市場(病院薬局、オンライン薬局、小売薬局)、購買パターン別市場(処方薬、市販薬)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業15社プロフィール動向などの情報も交えて、変形性関節症治療薬市場の現在と今後展開を予測分析していきます。

【レポート構成概要】
◆変形性関節症治療薬の世界市場予測2017-2024年
・市場規模(US$)

◆部位別、市場-2024年
・変形性膝関節症
・変形性股関節症
・変形性手関節症
・変形性小関節症
※(市場規模US$)

◆薬剤タイプ別、市場-2024年
関節内補充薬
非ステロイド性抗炎症薬
・イブプロフェン
・ジクロフェナク
・アスピリン
・ナプロキセン
・その他
鎮痛薬
・アセトアミノフェン
・デュロキセチン
コルチコステロイド
※(市場規模US$)

◆投薬経路別、市場-2024年
・経口
・非経口
・局所
※(市場規模US$)

◆流通経路別、市場-2024年
・病院薬局
・オンライン薬局
・小売薬局
※(市場規模US$)

◆購買パターン別、市場-2024年
・処方薬
・市販薬
※(市場規模US$)

◆主要国地域別市場-2024年
欧州
・イタリア、ドイツ、スペイン
・フランス、英国
・その他欧州
北米
・米国、カナダ
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※国地域別に全てのセグメントの細分化データ掲載、詳細は目次参照
※(市場規模US$)

◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会、課題)
・競合状況

◆変形性関節症治療薬の主要企業プロフィール動向
・SANOFI
・HORIZON THERAPEUTICS PLC
・JOHNSON & JOHNSON
・GLAXOSMITHKLINE PLC
・BAYER AG
・ABBOTT
・PFIZER, INC.
・ELI LILLY
・ANIKA THERAPEUTICS, INC.
・NOVARTIS
・FERRING PHARMACEUTICALS
・BIOVENTUS
・ZIMMER BIOMET HOLDINGS, INC.
・FIDIA FARMACEUTICI S.P.A.
・FLEXION THERAPEUTICS, INC.

(全148頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.3            MARKET SCOPE
1.3.1               MARKETS COVERED.. 18
1.3.2               YEARS CONSIDERED FOR THE STUDY
1.4            CURRENCY
1.5            LIMITATIONS
1.6            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH DATA
2.1.1               SECONDARY DATA
2.1.1.1             KEY DATA FROM SECONDARY SOURCES
2.1.2               PRIMARY DATA
2.1.2.1             KEY DATA FROM PRIMARY SOURCES
2.2            MARKET SIZE ESTIMATION
2.2.1               BOTTOM-UP APPROACH
2.2.2               TOP-DOWN APPROACH.. 24
2.3            MARKET BREAKDOWN AND DATA TRIANGULATION
2.4            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW
4.2            EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY ANATOMY (2018)
4.3            GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1               DRIVERS
5.2.1.1             RAPID GROWTH IN THE GERIATRIC AND OBESE POPULATIONS AND
THE ASSOCIATED INCREASE IN THE PREVALENCE OF OSTEOARTHRITIS
5.2.1.2             INCREASING INCIDENCE OF SPORTS INJURIES
5.2.2               RESTRAINTS
5.2.2.1             RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN OSTEOARTHRITIS TREATMENT
5.2.3               OPPORTUNITIES
5.2.3.1             EMERGING MARKETS
5.2.3.2             STRATEGIC COLLABORATIONS FOCUSED ON NEW PRODUCT DEVELOPMENT
5.2.4               CHALLENGES
5.2.4.1             AVAILABILITY OF ALTERNATIVE NON-DRUG PAIN MANAGEMENT THERAPIES

6.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY

6.1            INTRODUCTION
6.2            KNEE OSTEOARTHRITIS
6.2.1               RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS
6.3            HIP OSTEOARTHRITIS
6.3.1               SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS
6.4            HAND OSTEOARTHRITIS
6.4.1               RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH
6.5            SMALL-JOINT OSTEOARTHRITIS
6.5.1               RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE
THE PREVALENCE OF ANKLE OSTEOARTHRITIS

7.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE

7.1            INTRODUCTION
7.2            VISCOSUPPLEMENTATION AGENTS
7.2.1               VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2018
7.3            NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. 47
7.3.1               NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE VARIOUS POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH CORTICOSTEROIDS
7.3.1.1             IBUPROFEN
7.3.1.2             DICLOFENAC
7.3.1.3             ASPIRIN
7.3.1.4             NAPROXEN
7.3.1.5             OTHER MOLECULES
7.4            ANALGESICS
7.4.1               ACETAMINOPHEN
7.4.2               DULOXETINE
7.5            CORTICOSTEROIDS

8.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

8.1            INTRODUCTION
8.2            ORAL ROUTE
8.3            PARENTERAL ROUTE
8.4            TOPICAL ROUTE

9.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

9.1            INTRODUCTION
9.2            HOSPITAL PHARMACIES
9.3            ONLINE PHARMACIES
9.4            RETAIL PHARMACIES

10.. OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN

10.1          INTRODUCTION
10.2          PRESCRIPTION DRUGS
10.2.1             PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET
10.3          OVER-THE-COUNTER DRUGS
10.3.1             EASE OF PURCHASE AND ADMINISTRATION RESULTING IN A RISING DEMAND FOR OTC DRUGS

11.. OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION

11.1          INTRODUCTION
11.2          EUROPE
11.2.1             ITALY
11.2.2             GERMANY
11.2.3             SPAIN
11.2.4             FRANCE
11.2.5             UK
11.2.6             REST OF EUROPE
11.3          NORTH AMERICA
11.3.1             US
11.3.2             CANADA
11.4          ASIA PACIFIC
11.4.1             JAPAN
11.4.2             CHINA
11.4.3             INDIA
11.4.4             REST OF ASIA PACIFIC
11.5          REST OF THE WORLD

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          MARKET RANKING ANALYSIS, 2018
12.3          COMPETITIVE SCENARIO
12.3.1             PRODUCT LAUNCHES AND APPROVALS, 2016–2019
12.3.2             COLLABORATIONS, 2016–2019
12.3.3             EXPANSIONS, 2016–2019
12.3.4             ACQUISITIONS, 2016–2019
12.3.5             OTHER DEVELOPMENTS
12.4          COMPETITIVE LEADERSHIP MAPPING
12.4.1             VENDOR INCLUSION CRITERIA
12.4.2             VISIONARY LEADERS. 118
12.4.3             INNOVATORS
12.4.4             DYNAMIC DIFFERENTIATORS
12.4.5             EMERGING COMPANIES

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1          SANOFI
13.2          HORIZON THERAPEUTICS PLC
13.3          JOHNSON & JOHNSON
13.4          GLAXOSMITHKLINE PLC
13.5          BAYER AG
13.6          ABBOTT
13.7          PFIZER, INC.
13.8          ELI LILLY
13.9          ANIKA THERAPEUTICS, INC.
13.10       NOVARTIS
13.11       FERRING PHARMACEUTICALS
13.12       BIOVENTUS
13.13       ZIMMER BIOMET HOLDINGS, INC.
13.14       FIDIA FARMACEUTICI S.P.A.
13.15       FLEXION THERAPEUTICS, INC.
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14.. APPENDIX


LIST OF TABLES

TABLE 1               OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 2               KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 3               HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 4               HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 5               SMALL-JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 6               OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 7               OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 8               OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 9               OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 10             OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION,
2017–2024 (USD MILLION)
TABLE 11             OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION,
2017–2024 (USD MILLION)
TABLE 12             OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION,
2017–2024 (USD MILLION)
TABLE 13             OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION,
2017–2024 (USD MILLION)
TABLE 14             OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER MOLECULES, BY REGION, 2017–2024 (USD MILLION)
TABLE 15             OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 16             OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION,
2017–2024 (USD MILLION)
TABLE 17             OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2017–2024 (USD MILLION)
TABLE 18             OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION,
2017–2024 (USD MILLION)
TABLE 19             OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2017–2024 (USD MILLION)
TABLE 20             OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION)
TABLE 21             OSTEOARTHRITIS THERAPEUTICS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 22             OSTEOARTHRITIS THERAPEUTICS MARKET FOR PARENTERAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 23             OSTEOARTHRITIS THERAPEUTICS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 24             OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL,
2017–2024 (USD MILLION)
TABLE 25             OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES,
BY REGION, 2017–2024 (USD MILLION)
TABLE 26             OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 27             OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 28             OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2017–2024 (USD MILLION)
TABLE 29             OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 30             OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 31             OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 32             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 33             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 34             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 35             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 36             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 37             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 38             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 39             EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 40             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 41             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 42             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 44             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 45             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 46             ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 47             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 48             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 49             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 50             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 51             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 52             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 53             GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 54             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 55             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 56             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 57             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 58             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 59             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 60             SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 61             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 62             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 63             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 65             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 66             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 67             FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 68             UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 69             UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 70             UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 71             UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 72             UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 73             UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 74             UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2017–2024 (USD MILLION)
TABLE 75             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 76             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 77             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 78             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 79             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 80             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 81             ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 82             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 83             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 84             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 85             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 86             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 87             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 88             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 89             NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 90             US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 91             US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 92             US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 93             US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 94             US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 95             US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 96             US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2017–2024 (USD MILLION)
TABLE 97             CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 98             CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 99             CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100          CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 101          CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 102          CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 103          CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 104          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 105          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 106          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 107          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 108          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 109          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 110          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 111          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 112          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 113          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 114          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 115          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 116          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 117          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 118          JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 119          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 120          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 121          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 122          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 123          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 124          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 125          CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 126          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 127          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 128          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 129          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 130          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 131          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 132          INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 133          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 134          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 135          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 136          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 137          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 138          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 139          ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 140          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 141          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 142          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 143          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 144          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 145          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 146          ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)


LIST OF FIGURES

FIGURE 1             OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 2             RESEARCH DESIGN
FIGURE 3             BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4             OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH
FIGURE 5             OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH
FIGURE 6             DATA TRIANGULATION METHODOLOGY
FIGURE 7             OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2019 VS. 2024 (USD BILLION)
FIGURE 8             OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2019 VS. 2024 (USD BILLION)
FIGURE 9             OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2019 VS. 2024 (USD BILLION)
FIGURE 10          OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL,
2019 VS. 2024 (USD BILLION)
FIGURE 11          OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2019 VS. 2024 (USD BILLION)
FIGURE 12          OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2019 VS. 2024 (USD BILLION)
FIGURE 13          HIGH AND GROWING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
FIGURE 14          KNEE OSTEOARTHRITIS THERAPEUTICS SEGMENT TO DOMINATE
THE EUROPEAN MARKET IN 2019
FIGURE 15          CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 16          OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17          GERIATRIC POPULATION, BY REGION, 2017 VS. 2050
FIGURE 18          EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
FIGURE 19          ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
FIGURE 20          KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET FROM JANUARY 2016 TO AUGUST 2019
FIGURE 21          TOP 5 COMPANIES IN THE OSTEOARTHRITIS THERAPEUTICS MARKET
FIGURE 22          GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET: COMPETITIVE
LEADERSHIP MAPPING, 2019
FIGURE 23          SANOFI: COMPANY SNAPSHOT (2018)
FIGURE 24          HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2018)
FIGURE 25          JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018)
FIGURE 26          GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
FIGURE 27          BAYER AG: COMPANY SNAPSHOT (2018)
FIGURE 28          ABBOTT: COMPANY SNAPSHOT (2018)
FIGURE 29          PFIZER, INC.: COMPANY SNAPSHOT (2018)
FIGURE 30          ELI LILLY: COMPANY SNAPSHOT (2018)
FIGURE 31          ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 32          NOVARTIS: COMPANY SNAPSHOT (2018)
FIGURE 33          ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 34          FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2018)


掲載企業リスト

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。